Amphiphilic hemin-based nanoparticles with hypoxia tolerance and inflammation inhibition for osteoarthritis therapy.

Osteoarthritis (OA) remains a major clinical challenge, driven by persistent cytokine-based inflammation and poor regenerative capacity of hypoxic microenvironment and avascular cartilage. Despite recent advances, strategies that concurrently address…

Preview only. Read the full abstract at the source